Radiation dosimetry results from a phase II trial of Ibritumomab Tiuxetan (Zevalin™) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia
Gregory A. Wiseman, Thomas E. Witzig, Christine A. White, Bryan R. Leigh, William D. Erwin, Richard B. Sparks, Donald A. Podoloff, Russell J. Schilder, Nancy L. Bartlett, Stewart M. Spies, Antonio J. Grillo-López
Fingerprint
Dive into the research topics of 'Radiation dosimetry results from a phase II trial of Ibritumomab Tiuxetan (Zevalin™) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia'. Together they form a unique fingerprint.